BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 2411881)

  • 1. MOPP/ABV hybrid program: combination chemotherapy based on early introduction of seven effective drugs for advanced Hodgkin's disease.
    Klimo P; Connors JM
    J Clin Oncol; 1985 Sep; 3(9):1174-82. PubMed ID: 2411881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An update on the Vancouver experience in the management of advanced Hodgkin's disease treated with the MOPP/ABV Hybrid program.
    Klimo P; Connors JM
    Semin Hematol; 1988 Apr; 25(2 Suppl 2):34-40. PubMed ID: 2456621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial.
    Glick JH; Young ML; Harrington D; Schilsky RL; Beck T; Neiman R; Fisher RI; Peterson BA; Oken MM
    J Clin Oncol; 1998 Jan; 16(1):19-26. PubMed ID: 9440718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
    Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
    Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group.
    Connors JM; Klimo P; Adams G; Burns BF; Cooper I; Meyer RM; O'Reilly SE; Pater J; Quirt I; Sadura A; Shustik C; Skillings J; Sutcliffe S; Verma S; Yoshida S; Zee B
    J Clin Oncol; 1997 Apr; 15(4):1638-45. PubMed ID: 9193364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MOPP/EBV/CAD hybrid chemotherapy with or without limited radiotherapy in advanced or unfavorably presenting Hodgkin's disease: a report from the Italian Lymphoma Study Group.
    Gobbi PG; Pieresca C; Federico M; Di Renzo N; Narni F; Iannitto E; Grignani G; Cavanna L; Avanzini P; Partesotti G
    J Clin Oncol; 1993 Apr; 11(4):712-9. PubMed ID: 7683044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial.
    Duggan DB; Petroni GR; Johnson JL; Glick JH; Fisher RI; Connors JM; Canellos GP; Peterson BA
    J Clin Oncol; 2003 Feb; 21(4):607-14. PubMed ID: 12586796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hybrid MOPP/ABVD and radiotherapy in advanced Hodgkin's disease.
    Salvagno L; Sorarù M; Sotti G; Aversa S; Chiarion Sileni V; Mazzarotto R; Scarzello G; Bianco A; Pappagallo GL; Fiorentino MV
    Ann Oncol; 1995 Feb; 6(2):173-9. PubMed ID: 7540419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease.
    Fermé C; Eghbali H; Meerwaldt JH; Rieux C; Bosq J; Berger F; Girinsky T; Brice P; van't Veer MB; Walewski JA; Lederlin P; Tirelli U; Carde P; Van den Neste E; Gyan E; Monconduit M; Diviné M; Raemaekers JM; Salles G; Noordijk EM; Creemers GJ; Gabarre J; Hagenbeek A; Reman O; Blanc M; Thomas J; Vié B; Kluin-Nelemans JC; Viseu F; Baars JW; Poortmans P; Lugtenburg PJ; Carrie C; Jaubert J; Henry-Amar M;
    N Engl J Med; 2007 Nov; 357(19):1916-27. PubMed ID: 17989384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease.
    Connors JM; Klimo P
    Semin Hematol; 1987 Apr; 24(2 Suppl 1):35-40. PubMed ID: 2438780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bulky mediastinal Hodgkin's disease: results of a combined modality approach (ABVD/MOPP alternating chemotherapy plus radiation therapy).
    De Lena M; Ditonno P; Lorusso V; Timurian A; Pellecchia A; Brandi M; Berardi F; Marzullo F
    Haematologica; 1993; 78(4):230-5. PubMed ID: 7507457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study.
    Weiner MA; Leventhal B; Brecher ML; Marcus RB; Cantor A; Gieser PW; Ternberg JL; Behm FG; Wharam MD; Chauvenet AR
    J Clin Oncol; 1997 Aug; 15(8):2769-79. PubMed ID: 9256118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can MOPP be replaced in the treatment of advanced Hodgkin's disease?
    Canellos GP
    Semin Oncol; 1990 Feb; 17(1 Suppl 2):2-6. PubMed ID: 1689509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined modality therapy for advanced Hodgkin's disease: 15-year follow-up data.
    Prosnitz LR; Farber LR; Kapp DS; Scott J; Bertino JR; Fischer JJ; Cadman EC
    J Clin Oncol; 1988 Apr; 6(4):603-12. PubMed ID: 2451712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors.
    Gobbi PG; Broglia C; Levis A; La Sala A; Valentino F; Chisesi T; Sacchi S; Corbella F; Cavanna L; Iannitto E; Pavone V; Molica S; Corazza GR; Federico M
    Clin Cancer Res; 2006 Jan; 12(2):529-35. PubMed ID: 16428496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival and late effects in children with Hodgkin's lymphoma treated with MOPP/ABV and low-dose, extended-field irradiation.
    Chow LM; Nathan PC; Hodgson DC; Jenkin D; Weitzman S; Grant RM; Manson D; Bross A; Doyle JJ; Danjoux C; Greenberg ML
    J Clin Oncol; 2006 Dec; 24(36):5735-41. PubMed ID: 17179107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term follow-up of survival in Hodgkin's lymphoma.
    Canellos GP; Niedzwiecki D; Johnson JL
    N Engl J Med; 2009 Dec; 361(24):2390-1. PubMed ID: 20007568
    [No Abstract]   [Full Text] [Related]  

  • 18. MACOP-B and VACOP-B in diffuse large cell lymphomas and MOPP/ABV in Hodgkin's disease.
    O'Reilly SE; Hoskins P; Klimo P; Connors JM
    Ann Oncol; 1991 Jan; 2 Suppl 1():17-23. PubMed ID: 1710485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MOPP/ABV/CAD chemotherapy with and without recombinant human granulocyte-macrophage colony stimulating factor in untreated, unfavorable prognosis Hodgkin's disease.
    Riccardi A; Gobbi P; Danova M; Giordano M; Pieresca C; Bertoloni D; Brugnatelli S; Ascari E
    Haematologica; 1993; 78(1):44-8. PubMed ID: 7684012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involved-field radiotherapy for advanced Hodgkin's lymphoma.
    Aleman BM; Raemaekers JM; Tirelli U; Bortolus R; van 't Veer MB; Lybeert ML; Keuning JJ; Carde P; Girinsky T; van der Maazen RW; Tomsic R; Vovk M; van Hoof A; Demeestere G; Lugtenburg PJ; Thomas J; Schroyens W; De Boeck K; Baars JW; Kluin-Nelemans JC; Carrie C; Aoudjhane M; Bron D; Eghbali H; Smit WG; Meerwaldt JH; Hagenbeek A; Pinna A; Henry-Amar M;
    N Engl J Med; 2003 Jun; 348(24):2396-406. PubMed ID: 12802025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.